PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2025

  • ID: 4142833
  • Report
  • Region: Global
  • 510 pages
  • GlobalData
1 of 4

FEATURED COMPANIES

  • AstraZeneca
  • Novartis
  • Pfizer
  • Roche
  • MORE
PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2025

Summary:

Human Epidermal growth factor Receptor type 2 (HER2-) breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. HER2-negative breast cancer can be subdivided into hormone receptor-positive (HER2-/HR+), and triple negative breast cancer (TNBC). The prognoses of HER2-/HR+ and TNBC differ dramatically, as patients with TNBC progress more rapidly towards metastatic disease and only respond to chemotherapy agents.

It is estimated that the value of the HER2- breast cancer market in the 8MM in 2015 was $5.4B. This market is defined as the sales of generics and major branded drugs commonly prescribed for HER2- breast cancer patients across the 8MM. In HER2- breast cancer, generics accounted for 41.4% of drug sales in 2015, corresponding to $3.18B sales. Just over half of the overall sales, $3.20B (59.0%), were generated in the US, with the 5EU representing the next largest region by sales, estimated at $1.34B (24.7%). Japan and China contributed the smallest proportions of sales to the global HER2- breast cancer market, with 2015 sales of $554M (10.2%) and $337M (6.2%), respectively.

In 2015, the HER2- breast cancer market was dominated by the use of generic endocrine therapy and chemotherapy in both the early disease and metastatic settings. Interestingly, companies have adopted a common strategy in HER2- breast cancer of utilizing existing standard of care (SOC) treatments and establishing combinations with new premium-priced targeted agents in an attempt to strengthen their position in the market. In the TNBC segment, combinations are likely to improve the uptake of new premium-priced agents; however, in HER2-/HR+ patients, combinations will offer a dual advantage by driving both treatment uptake and longer treatment duration.

The report “PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2025” highlights the significant unmet need for expansion in the HER2- breast cancer marker across the eight major markets; it also discusses the associated commercial opportunities for new market entrants to gain a foothold in the market. It is anticipated that the HER2- breast cancer market to almost double, from $5.43B to $10.58B, over the forecast period of 2015-2025.

Scope:

- Overview of HER2- breast cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, treatment guidelines and disease management.
- Annualized HER2- breast cancer therapeutics market revenue, average cost of therapy and treatment usage pattern data from 2015 and forecast for seven years to 2025.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the HER2- breast cancer therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of middle- to late-stage pipeline drugs.
- Analysis of the current and future market competition in the global HER2- breast cancer therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the global HER2- breast cancer therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global HER2- breast cancer therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global HER2- breast cancer therapeutics market from 2015-2025.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AstraZeneca
  • Novartis
  • Pfizer
  • Roche
  • MORE
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.1.3 Basic Breast Anatomy
3.2 Disease Classification/Staging Systems
3.3 Symptoms
3.4 Prognosis
3.5 Quality of Life
4 Epidemiology
4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global Trends
4.3.1 US
4.3.2 5EU
4.3.3 Japan
4.3.4 China (Urban)
4.3.5 Prevalence and Survival
4.4 Forecast Methodology
4.4.1 Sources Used Tables
4.4.2 Forecast Assumptions and Methods
4.4.3 Sources Not Used
4.5 Epidemiological Forecast for Non-Invasive DCIS Breast Cancer (2015-2025)
4.5.1 Diagnosed Incident Cases of Non-Invasive DCIS Breast Cancer
4.5.2 Diagnosed Incident Cases of Non-Invasive DCIS Breast Cancer by HER2 Status
4.6 Epidemiological Forecast for Invasive Breast Cancer (2015-2025)
4.6.1 Diagnosed Incident Cases of Invasive Breast Cancer
4.6.2 Age-Specific Diagnosed Incident Cases of Invasive Breast Cancer
4.6.3 Age-Standardized Diagnosed Incidence of Invasive Breast Cancer
4.6.4 Five-Year Diagnosed Prevalent Cases of Invasive Breast Cancer
4.6.5 Diagnosed Incident Cases of Invasive Breast Cancer by Stage at Diagnosis
4.6.6 Diagnosed Incident Cases of Invasive Breast Cancer by HER2 Status
4.6.7 Diagnosed Incident Cases of HER2+ Invasive Breast Cancer by Stage at Diagnosis, Menopausal Status, and Site of Metastasis
4.6.8 Diagnosed Incident Cases of HER2-/HR+ Breast Cancer by Stage at Diagnosis, Menopausal Status, and Type of Biomarker Expression
4.6.9 Diagnosed Incident Cases of TN Breast Cancer by Stage at Diagnosis and BRCA Expression
4.7 Discussion
4.7.1 Epidemiological Forecast Insight
4.7.2 Limitations of the Analysis
4.7.3 Strengths of the Analysis
5 Disease Management
5.1 Diagnosis and Treatment Overview
5.1.1 Screening and Diagnosis
5.1.2 Treatment Overview of Loco-Regional Breast Cancer
5.1.3 Neoadjuvant and Adjuvant Treatment Regimen
5.1.4 Treatment of Metastatic HR+ Disease
5.1.5 Treatment of Metastatic TNBC
5.1.6 Treatment Guidelines and Leading Prescribed Drugs
5.2 US
5.2.1 Diagnosis
5.2.2 Clinical Practice
5.3 France
5.3.1 Diagnosis
5.3.2 Clinical Practice
5.4 Germany
5.4.1 Diagnosis
5.4.2 Clinical Practice
5.5 Italy
5.5.1 Diagnosis
5.5.2 Clinical Practice
5.6 Spain
5.6.1 Diagnosis
5.6.2 Clinical Practice
5.7 UK
5.7.1 Diagnosis
5.7.2 Clinical Practice
5.8 Japan
5.8.1 Diagnosis
5.8.2 Clinical Practice
5.9 China
5.9.1 Diagnosis
5.9.2 Clinical Practice
6 Competitive Assessment
6.1 Overview
6.2 Product Profiles (Branded Therapies)
6.2.1 Ibrance (palbociclib)
6.2.2 Abraxane (nab-paclitaxel)
6.2.3 Afinitor (everolimus)
6.2.4 Avastin (bevacizumab)
6.2.5 Halaven (eribulin mesylate)
6.2.6 Ixempra (ixabepilone)
6.2.7 Faslodex (fulvestrant)
6.2.8 Doxil/Caelyx (pegylated liposomal doxorubicin)
6.3 Product Profiles (Hormonal Agents)
6.3.1 Tamoxifen
6.3.2 Aromatase Inhibitors
7 Unmet Needs and Opportunities
7.1 Overview
7.1.1 Defined Treatment Plan for BRCA+ Patients and the Prevention of Prophylactic Surgeries
7.1.2 Targeted Treatment Options for Triple Negative Breast Cancer Patients
7.1.3 Treatment of Brain Metastasis
7.1.4 For HR+ Patients, Reduced Resistance to Hormonal Agents
7.1.5 Improved Convenience of Administration of Hormonal Agents
8 Pipeline Assessment
8.1 Overview
8.2 CDK4/6 inhibitors
8.2.1 Abemaciclib (LY2835219)
8.2.2 Ribociclib (LEE011)
8.3 Poly ADP-Ribose Polymerase Inhibitors
8.3.1 Lynparza (olaparib)
8.3.2 Talazoparib (BMN 673)
8.3.3 Veliparib (ABT-888)
8.3.4 Niraparib (MK4827)
8.4 Phosphoinositide 3 Kinase Inhibitors
8.4.1 Buparlisib (BKM- 120)
8.4.2 Alpelisib (BYL-719)
8.4.3 Taselisib (GDC-0032)
8.5 PD-1/PD-L1 Checkpoint Inhibitors
8.5.1 Tecentriq (atezolizumab)
8.5.2 Keytruda (pembrolizumab)
8.6 Histone Deacetylase Inhibitors
8.6.1 Entinostat
8.6.2 Epidaza (chidamide)
8.7 Antibody Drug Conjugates
8.7.1 Sacituzimab govitecan (IMMU-132)
8.7.2 Glembatumumab vedotin (CDX-011)
8.8 Others
8.8.1 Xtandi (enzalutamide)
8.9 Promising Drugs in Early Stage Clinical Development
8.9.1 Seviteronel
8.9.2 Ipatasertib
8.9.3 Vanctitumab
8.9.4 IDO Checkpoint Inhibitors
9 Current and Future Players
9.1 Overview
9.2 Trends in Corporate Strategy
9.3 Company Profiles
9.3.1 Pfizer
9.3.2 Novartis
9.3.3 Roche
9.3.4 AstraZeneca
10 Market Outlook
10.1 Global Markets
10.1.1 Forecast
10.1.2 Drivers and Barriers - Global Issues
10.2 US
10.2.1 Forecast
10.2.2 Key Events
10.2.3 Drivers and Barriers
10.3 5EU
10.3.1 Forecast
10.3.2 Key Events
10.3.3 Drivers and Barriers
10.4 Japan
10.4.1 Forecast
10.4.2 Key Events
10.4.3 Drivers and Barriers
10.5 China
10.5.1 Forecast
10.5.2 Key Events
10.5.3 Drivers and Barriers
11 Appendix
11.1 Bibliography
11.2 Abbreviations
11.3 Methodology
11.4 Forecasting Methodology
11.4.1 Diagnosed Patients with HER2- Breast Cancer
11.4.2 Percent Drug-Treated Patients
11.4.3 Drugs Included in Each Therapeutic Class
11.4.4 Launch and Patent Expiration Dates
11.4.5 General Pricing Assumptions
11.4.6 Average Body Weight and Surface Area Across the 8MM
11.4.7 General Forecast Assumptions
11.4.8 Individual Drug Assumptions
11.4.9 TS-1 Assumptions
11.4.10 Generic Erosion
11.4.11 Pricing of Pipeline Agents
11.5 Primary Research - Key Opinion Leaderss Interviewed for This Report
11.6 Primary Research - High-Prescribers Surveyed for this Report
11.7 About the Authors
11.7.1 Author
11.7.2 Epidemiologist
11.7.3 Therapy Director
11.7.4 Epidemiology Director
11.7.5 Global Director of Therapy Analysis and Epidemiology
11.8 About Us
11.9 Disclaimer

1.1 List of Tables
Table 1: Molecular Subtypes of Breast Cancer
Table 2: AJCC Stage Definitions for Breast Cancer
Table 3: Prognosis for Breast Cancer
Table 4: Risk Factors and Comorbidities for Breast Cancer
Table 5: 8MM, Most Recent Five-Year Relative Survival for Invasive Breast Cancer, Women (%)
Table 6: 8MM, Sources of Epidemiological Data Used to Forecast Diagnosed Incidence of Non-Invasive DCIS Breast Cancer
Table 7: 8MM, Sources of Epidemiological Data Used to Forecast Diagnosed Incident Cases of Non-Invasive DCIS Breast Cancer by HER2 Status
Table 8: 8MM, Sources of Epidemiological Data Used to Forecast Diagnosed Incidence of Invasive Breast Cancer
Table 9: 8MM, Sources of Epidemiological Data Used to Forecast Invasive Breast Cancer by HER2 Status
Table 10: 8MM, Sources of Epidemiological Data Used to Forecast the Relative Survival of Invasive Breast Cancer
Table 11: 8MM, Sources of Epidemiological Data Used to Forecast HER2+ Invasive Breast Cancer by Stage at Diagnosis
Table 12: 8MM, Sources of Epidemiological Data Used to Forecast HER2-, HR+ Invasive Breast Cancer by Stage at Diagnosis
Table 13: 8MM, Sources of Epidemiological Data Used to Forecast TN Invasive Breast Cancer by Stage at Diagnosis
Table 14: 8MM, Sources of Epidemiological Data Used to Forecast HER2-Specific Invasive Breast Cancer by Menopausal Status
Table 15: 8MM, Sources of Epidemiological Data Used to Forecast HER2+ Invasive Breast Cancer by Site of Metastasis
Table 16: 8MM, Sources of Epidemiological Data Used to Forecast HER2-Specific Invasive Breast Cancer by Type of Biomarker Expression
Table 17: 8MM, Sources Not Used in Epidemiological Analysis of Breast Cancer
Table 18: 8MM, Diagnosed Incident Cases of Non-Invasive DCIS Breast Cancer, Women, Ages =18 Years, N, Select Years, 2015-2025
Table 19: 8MM, Diagnosed Incident Cases of Non-Invasive DCIS Breast Cancer by HER2 Status, Women, Ages =18 Years, N, 2015
Table 20: 8MM, Diagnosed Incident Cases of Invasive Breast Cancer, Women, Ages =18 Years, N, Select Years, 2015-2025
Table 21: 8MM, Age-Specific Diagnosed Incident Cases of Invasive Breast Cancer, Women, Ages =18 Years, N (Row %), 2015
Table 22: 8MM, Five-Year Diagnosed Prevalent Cases of Invasive Breast Cancer, Women, Ages =18 Years, N, Select Years, 2015-2025
Table 23: 8MM, Diagnosed Incident Cases of Invasive Breast Cancer by Stage at Diagnosis, Women, Ages =18 Years, N, 2015
Table 24: 8MM, Diagnosed Incident Cases of Invasive Breast Cancer by HER2 Status, Women, Ages =18 Years, N, 2015
Table 25: Treatment Guidelines for HER2- Breast Cancer
Table 26: Most Prescribed Regimens for HER2- Breast Cancer by Drug Class in the Global Markets, 2015
Table 27: Country Profile - US
Table 28: Country Profile - France
Table 29: Country Profile - Germany
Table 30: Country Profile - Italy
Table 31: Country Profile - Spain
Table 32: Country Profile - UK
Table 33: Country Profile - Japan
Table 34: Country Profile - China
Table 35: Product Profile - Ibrance
Table 36: Summary of the Results of the PALOMA-2 Trial
Table 37: Summary of the Results of the PALOMA-3 Trial
Table 38: Safety profile of Ibrance + letrozole
Table 39: Safety Profile of Ibrance in Combination with Faslodex
Table 40: Ibrance SWOT Analysis, 2016
Table 41: Product Profile - Abraxane
Table 42: Efficacy of Abraxane
Table 43: Safety Profile of Abraxane
Table 44: Abraxane SWOT Analysis, 2016
Table 45: Product Profile - Afinitor (everolimus)
Table 46: Efficacy of Afinitor in Second-Line HER2-/HR+ Advanced Breast Cancer
Table 47: Safety Profile of Afinitor
Table 48: Afinitor SWOT Analysis, 2016
Table 49: Product Profile - Avastin
Table 50: Efficacy of Avastin in First Line Metastatic Breast Cancer
Table 51: Safety of Avastin in First-Line Metastatic Breast Cancer
Table 52: Avastin SWOT Analysis, 2016
Table 53: Product Profile - Halaven
Table 54: Efficacy of Halaven
Table 55: Safety Profile of Halaven
Table 56: Halaven SWOT Analysis, 2016
Table 57: Product Profile - Ixempra
Table 58: Efficacy of Ixempra Monotherapy
Table 59: Efficacy of Ixempra in Combination with Xeloda
Table 60: Safety Profile of Ixempra
Table 61: Ixempra SWOT Analysis, 2016
Table 62: Product Profile - Faslodex
Table 63: Efficacy of Faslodex in the First Line
Table 64: Efficacy of Faslodex Monotherapy in the Second Line
Table 65: Efficacy of Faslodex in the First Line
Table 66: Safety of Faslodex in the First Line
Table 67: Safety of Faslodex in the Second Line
Table 68: Faslodex SWOT Analysis, 2016
Table 69: Product Profile - Doxil
Table 70: Doxil SWOT Analysis, 2016
Table 71: Product Profile - Nolvadex/Soltamox
Table 72: AI Approvals in the 8MM
Table 73: Unmet Need and Opportunity in HER2- Breast Cancer
Table 74: Product Profile - Abemaciclib (LY2835219)
Table 75: Efficacy of Abemaciclib in Monotherapy in Pretreated HER2-/HR+ Metastatic Breast Cancer Patients (MONARCH 1 NCT02102490)
Table 76: Safety of Abemaciclib in Monotherapy in Pretreated HER2-/HR+ Metastatic Breast Cancer Patients
Table 77: Abemaciclib SWOT Analysis, 2016
Table 78: Product Profile - Ribociclib
Table 79: Efficacy of Ribociclib in Combination with Letrozole in HER2-/HR+ Metastatic Breast Cancer Patients (MONALEESA 2, NCT01958021)
Table 80: Most Common AEs of Ribociclib in Combination with Letrozole in HER2-/HR+ Metastatic Breast Cancer Patients (MONALEESA 2, NCT01958021)
Table 81: Ribociclib SWOT Analysis, 2015
Table 82: Product Profile - Lynparza
Table 83: Summary of the Results of the ICEBERG 1 Phase II Trial (NCT00494234)
Table 84: Summary of the Most Commonly Reported AEs, Occurring in at Least 20% of Patients With Advanced Ovarian Cancers Treated with Lynparza Monotherapy
Table 85: Lynparza SWOT Analysis, 2016
Table 86: Product Profile - Talazoparib
Table 87: Summary of the Most Commonly Reported AEs in Patients Treated with Talazoparib Monotherapy
Table 88: Talazoparib SWOT Analysis, 2016
Table 89: Product Profile - Veliparib
Table 90: Veliparib SWOT Analysis, 2016
Table 91: Product Profile - Niraparib
Table 92: Summary of the Main Reported AEs in Ovarian Cancer Patients Treated with Niraparib
Table 93: Niraparib SWOT Analysis 2016
Table 94: Product Profile - Buparlisib (BKM-120)
Table 95: Summary of the Results of the Trial of Buparlisib + Faslodex vs. Faslodex
Table 96: Summary of AEs From the Trial of Buparlisib + Faslodex vs. Faslodex
Table 97: Buparlisib SWOT Analysis
Table 98: Product Profile - Alpelisib (BYL- 719)
Table 99: Summary of the Results of the Alpelisib Trial
Table 100: Summary of AEs from the Trial of Alpelisib
Table 101: Alpelisib SWOT Analysis
Table 102: Product Profile - Taselisib (GDC-0032)
Table 103: Summary of the Results of the Taselisib Trial
Table 104: Summary of the Safety of Taselisib
Table 105: Taselisib SWOT Analysis
Table 106: Product Profile - Tecentriq
Table 107: Summary of the Results of the Phase Ib Trial of Tecentriq in Combination with Abraxane in Patients with mTNBC (Genetech, NCT01633970)
Table 108: Summary of AEs from the Phase Ib Trial of Tecentriq + Abraxane in Patients with mTNBC (Genetech, NCT01633970)
Table 109: Tecentriq SWOT Analysis, 2016
Table 110: Product Profile - Keytruda (Pembrolizumab)
Table 111: Summary of the Results of Keytruda in HER2-/HR+ Patients in the KEYNOTE-028 Trial (MSD, NCT02054806)
Table 112: Summary of AEs of All Grades for Keytruda in HER2-/HR+ Patients in the Keytruda KEYNOTE-028 Trial (MSD, NCT02054806)
Table 113: Summary of Grade 3-4 AEs from the Trial of Keytruda (MSD, NCT02054806)
Table 114: Keytruda SWOT Analysis, 2016
Table 115: Product Profile - Entinostat
Table 116: Efficacy Results from the ENCORE301 Trial of Exemestane + Entinostat vs. Exemestane + Placebo
Table 117: Most Commonly Reported AEs from the ENCORE301 trial of Exemestane + Entinostat vs. Exemestane + Placebo
Table 118: Entinostat SWOT, 2016
Table 119: Product Profile - Epidaza
Table 120: Most Commonly Reported AEs from the Phase II Trial of Epidaza + Exemestane
Table 121: Epidaza SWOT Analysis
Table 122: Product Profile - Sacituzumab Govitecan
Table 123: Summary of the Results of Sacituzimab Govitecan Phase I/II Trial in Metastatic TNBC (Immunomedics Inc., NCT01631552)
Table 124: Summary of AEs from the Phase I/II Trial of Sacituzimab Govitecan (Immunomedics Inc., NCT01631552)
Table 125: Sacituzimab Govitecan SWOT, 2016
Table 126: Product Profile - Glembatumumab vedotin
Table 127: Efficacy Results of the Phase IIb EMERGE Trial of Glembatumumab Vedotin Monotherapy in Metastatic TNBC (NCT01156753)
Table 128: Safety Results of the Phase IIb EMERGE Trial of Glembatumumab Vedotin Monotherapy in Solid Tumors
Table 129: Glembatumumab Vedotin SWOT, 2016
Table 130: Product Profile - Xtandi
Table 131: Summary of the Results of ENZA Phase II Xtandi Trial (NCT01889238)
Table 132: Summary of the Results of Xtandi Trial
Table 133: Xtandi SWOT Analysis, 2016
Table 134: Early Stage Clinical Development in HER2- Breast Cancer
Table 135: Key Companies in the Disease HER2- Breast Cancer Market in the 8MM, 2015
Table 136: Pfizer’s HER2- Metastatic Breast Cancer Portfolio Assessment, 2016
Table 137: Novartis’ HER2- Metastatic Breast Cancer Portfolio Assessment, 2016
Table 138: Roche’s HER2- Breast Cancer Portfolio Assessment, 2016
Table 139: AZ’s HER2- Breast Cancer Portfolio Assessment, 2016
Table 140: Global HER2- Breast Cancer Market - Drivers and Barriers, 2015-2025
Table 141: Key Events Impacting Sales for HER2-/HR+ in the US, 2015-2025
Table 142: Key Events Impacting Sales for TNBC in the US, 2015-2025
Table 143: US HER2- Breast Cancer Market - Drivers and Barriers, 2015-2025
Table 144: Key Events Impacting Sales for HER2-/HR+ Breast Cancer in the 5EU, 2015-2025
Table 145: Key Events Impacting Sales for TNBC in the 5EU, 2015-2025
Table 146: 5EU HER2- Breast Cancer Market - Drivers and Barriers, 2015-2025
Table 147: Key Events Impacting Sales for HER2-/HR+ breast cancer in Japan, 2015-2025
Table 148: Key Events Impacting Sales for TNBC in Japan, 2015-2025
Table 149: Japanese HER2- Breast Cancer Market - Drivers and Barriers, 2015-2025
Table 150: Key Events Impacting Sales for HER2-/HR+ Breast Cancer in China, 2015-2025
Table 151: Key Events Impacting Sales for TNBC in China, 2015-2025
Table 152: Chinese HER2- Breast Cancer Market - Drivers and Barriers, 2015-2025
Table 153: Key Launch Dates in HER2- Breast Cancer
Table 154: Key Patent Expiries
Table 155: Average Body Weight and Surface Area Across the 8MM
Table 156: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country

1.2 List of Figures
Figure 1: Basic Breast Anatomy, Including Key Lymph Nodes
Figure 2: 8MM, Crude Diagnosed Incidence Rates of Invasive Breast Cancer, Ages =18 Years, Women, Cases per 100,000 Population, 2005?2014
Figure 3: Case Flow Map
Figure 4: 8MM, Diagnosed Incident Cases of Non-Invasive DCIS Breast Cancer, Women, Ages =18 Years, Selected Years, 2015-2025
Figure 5: 8MM, Diagnosed Incident Cases of Non-Invasive DCIS Breast Cancer by HER2 Status, Women, Ages =18 Years, 2015
Figure 6: 8MM, Diagnosed Incident Cases of Invasive Breast Cancer, Women, Ages =18 Years, Selected Years, 2015-2025
Figure 7: 8MM, Age-Specific Diagnosed Incident Cases of Invasive Breast Cancer, Women, Ages =18 Years, N, 2015
Figure 8: 8MM, Age-Standardized Diagnosed Incident Cases of Invasive Breast Cancer, Women, Ages =18 Years, N, 2015
Figure 9: 8MM, Five-Year Diagnosed Prevalent Cases of Invasive Breast Cancer, Women, Ages =18 Years, Select Years, 2015-2025
Figure 10: 8MM, Diagnosed Incident Cases of Invasive Breast Cancer by Stage at Diagnosis, Women, Ages =18 Years, 2015
Figure 11: 8MM, Diagnosed Incident Cases of Breast Cancer by HER2 Status, Women, Ages =18 Years, 2015
Figure 12: 8MM, Diagnosed Incident Cases of HER2+ Invasive Breast Cancer by Stage at Diagnosis, Women, Ages =18 Years, 2015
Figure 13: 8MM, Proportion of HER2+/HR+ Diagnosed Incident Cases of Invasive Breast Cancer by Menopausal Status, Women, Ages =18 Years, 2015
Figure 14: 8MM, Proportion of HER2+/HR- Diagnosed Incident Cases of Invasive Breast Cancer by Menopausal Status, Women, Ages =18 Years, 2015
Figure 15: 8MM, Diagnosed Incident Cases of HER2+ Invasive Breast Cancer by Site of Metastasis, Women, Ages =18 Years, 2015
Figure 16: 8MM, Diagnosed Incident Cases of HER2-/HR+ Invasive Breast Cancer by Stage at Diagnosis, Women, Ages =18 Years, 2015
Figure 17: 8MM, Proportion of HER2-/HR+ Diagnosed Incident Cases of Invasive Breast Cancer by Menopausal Status, Women, Ages =18 Years, 2015
Figure 18: 8MM, Diagnosed Incident Cases of HER2-/HR+ Invasive Breast Cancer by Type of Biomarker Expression, Women, Ages =18 Years, 2015
Figure 19: 8MM, Diagnosed Incident Cases of TN Invasive Breast Cancer by Stage at Diagnosis, Women, Ages =18 Years, 2015
Figure 20: 8MM, Diagnosed Incident Cases of TN Invasive Breast Cancer with BRCA Expression, Women, Ages =18 Years, 2015
Figure 21: Overview of Non-Invasive and Invasive Breast Cancer Treatment
Figure 22: Neoadjuvant/Adjuvant Settings Treatment Paradigm in HER2- Breast Cancer
Figure 23: Key Late-Stage Key Clinical Trials of Ibrance
Figure 24: Key Late-Stage Key Clinical Trials of Abraxane
Figure 25: Key Late-Stage Key Clinical Trials of Afinitor
Figure 26: Key Late-Stage Clinical Trials of Avastin
Figure 27: Key Late-Stage Clinical Trials of Halaven
Figure 28: Key Late-Stage Clinical Trials of Ixempra
Figure 29: Key Late-Stage Clinical Trials of Faslodex
Figure 30: Late-Stage Clinical Trials of Drugs in HR+ Breast Cancer
Figure 31: Late-Stage Clinical Trials of Drugs in TNBC
Figure 32: Key Late-Stage Clinical Trials of Abemaciclib
Figure 33: Clinical and Commercial Positioning of Abemaciclib
Figure 34: Key Late-Stage Clinical Trials of Ribociclib
Figure 35: Clinical and Commercial Positioning of Ribociclib
Figure 36: Key Late-Stage Clinical Trials of Lynparza
Figure 37: Clinical and Commercial Positioning of Lynparza
Figure 38: Key Late-Stage Clinical Trials of Talazoparib
Figure 39: Clinical and Commercial Positioning of Talazoparib
Figure 40: Key Late-Stage Clinical Trials of Veliparib
Figure 41: Clinical and Commercial Positioning of Veliparib
Figure 42: Key Late-Stage Clinical Trials of Niraparib
Figure 43: Clinical and Commercial Positioning of Niraparib
Figure 44: Key Late-Stage Clinical Trials of Buparlisib
Figure 45: Clinical and Commercial Positioning of Buparlisib
Figure 46: Key Late-Stage Clinical Trials of Alpelisib
Figure 47: Clinical and Commercial Positioning of Alpelisib
Figure 48: Key Late-Stage Clinical Trials of Taselisib
Figure 49: Clinical and Commercial Positioning of Taselisib
Figure 50: Key Late-Stage Clinical Trials of Tecentriq
Figure 51: Clinical and Commercial Positioning of Tecentriq
Figure 52: Key Late-Stage Clinical Trials of Keytruda
Figure 53: Clinical and Commercial Positioning of Keytruda
Figure 54: Key Late-Stage Clinical Trials of Entinostat
Figure 55: Clinical and Commercial Positioning of Entinostat
Figure 56: Key Late-Stage Clinical Trials of Epidaza
Figure 57: Clinical and Commercial Positioning of Epidaza
Figure 58: Key Late-Stage Clinical Trials of Sacituzumab Govitecan
Figure 59: Clinical and Commercial Positioning of sacituzimab govitecan
Figure 60: Key Late-Stage Clinical Trials of Glembatumumab Vedotin
Figure 61: Clinical and Commercial Positioning of Glembatumumab Vedotin
Figure 62: Key Late-Stage Clinical Trials of Xtandi
Figure 63: Clinical and Commercial Positioning of Xtandi
Figure 64: Global Sales of Branded Products for HER2- Breast Cancer by Company, 2015 and 2025
Figure 65: Company Portfolio Gap Analysis in HER2- Breast Cancer, 2015-2025
Figure 66: Pfizer SWOT Analysis in HER2- Metastatic Breast Cancer, 2016
Figure 67: Novartis SWOT Analysis in HER2- Metastatic Breast Cancer, 2016
Figure 68: Roche SWOT Analysis in HER2- Metastatic Breast Cancer, 2016
Figure 69: Roche SWOT Analysis in HER2- Metastatic Breast Cancer, 2016
Figure 70: Global Sales ($M) for HER2- Breast Cancer by Region, 2015-2025
Figure 71: Global Sales for HER2- Breast Cancer by Drug, 2015-2025
Figure 72: Sales for HER2-/HR+ Breast Cancer in the US by Drug, 2015-2025
Figure 73: Sales for TNBC Breast Cancer in the US by Drug, 2015-2025
Figure 74: Sales for HER2-/HR+ Breast Cancer in the 5EU by Drug, 2015-2025
Figure 75: Sales for TNBC Breast Cancer in the 5EU by Drug, 2015-2025
Figure 76: Sales for HER2-/HR+ Breast Cancer in Japan by Drug, 2015-2025
Figure 77: Sales for TNBC Breast Cancer in Japan by Drug, 2015-2025
Figure 78: Sales for HER2-/HR+ Breast Cancer in China by Drug, 2015-2025
Figure 79: Sales for TNBC Breast Cancer in China by Drug, 2015-
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Pfizer
  • Novartis
  • Roche
  • AstraZeneca
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll